350 related articles for article (PubMed ID: 36142171)
1. Mucins and CFTR: Their Close Relationship.
Okuda K; Shaffer KM; Ehre C
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142171
[TBL] [Abstract][Full Text] [Related]
2. Mucus aberrant properties in CF: Insights from cells and animal models.
Ehre C; Hansson GC; Thornton DJ; Ostedgaard LS
J Cyst Fibros; 2023 Mar; 22 Suppl 1(Suppl 1):S23-S26. PubMed ID: 36117114
[TBL] [Abstract][Full Text] [Related]
3. Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties
Morrison CB; Shaffer KM; Araba KC; Markovetz MR; Wykoff JA; Quinney NL; Hao S; Delion MF; Flen AL; Morton LC; Liao J; Hill DB; Drumm ML; O'Neal WK; Kesimer M; Gentzsch M; Ehre C
Eur Respir J; 2022 Feb; 59(2):. PubMed ID: 34172469
[TBL] [Abstract][Full Text] [Related]
4. Mucus, mucins, and cystic fibrosis.
Morrison CB; Markovetz MR; Ehre C
Pediatr Pulmonol; 2019 Nov; 54 Suppl 3(Suppl 3):S84-S96. PubMed ID: 31715083
[TBL] [Abstract][Full Text] [Related]
5. Cystic fibrosis: an inherited disease affecting mucin-producing organs.
Ehre C; Ridley C; Thornton DJ
Int J Biochem Cell Biol; 2014 Jul; 52():136-45. PubMed ID: 24685676
[TBL] [Abstract][Full Text] [Related]
6. Airway mucus in cystic fibrosis.
Puchelle E; Bajolet O; Abély M
Paediatr Respir Rev; 2002 Jun; 3(2):115-9. PubMed ID: 12297057
[TBL] [Abstract][Full Text] [Related]
7. CFTR, mucins, and mucus obstruction in cystic fibrosis.
Kreda SM; Davis CW; Rose MC
Cold Spring Harb Perspect Med; 2012 Sep; 2(9):a009589. PubMed ID: 22951447
[TBL] [Abstract][Full Text] [Related]
8. Evidence of early increased sialylation of airway mucins and defective mucociliary clearance in CFTR-deficient piglets.
Caballero I; Ringot-Destrez B; Si-Tahar M; Barbry P; Guillon A; Lantier I; Berri M; Chevaleyre C; Fleurot I; Barc C; Ramphal R; Pons N; Paquet A; Lebrigand K; Baron C; Bähr A; Klymiuk N; Léonard R; Robbe-Masselot C
J Cyst Fibros; 2021 Jan; 20(1):173-182. PubMed ID: 32978064
[TBL] [Abstract][Full Text] [Related]
9. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium.
Zhang L; Button B; Gabriel SE; Burkett S; Yan Y; Skiadopoulos MH; Dang YL; Vogel LN; McKay T; Mengos A; Boucher RC; Collins PL; Pickles RJ
PLoS Biol; 2009 Jul; 7(7):e1000155. PubMed ID: 19621064
[TBL] [Abstract][Full Text] [Related]
10. Modulator Combination Improves In Vitro the Microrheological Properties of the Airway Surface Liquid of Cystic Fibrosis Airway Epithelia.
Ludovico A; Moran O; Baroni D
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232697
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis transmembrane conductance regulator is expressed in mucin granules from Calu-3 and primary human airway epithelial cells.
LeSimple P; Goepp J; Palmer ML; Fahrenkrug SC; O'Grady SM; Ferraro P; Robert R; Hanrahan JW
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):511-6. PubMed ID: 23742042
[TBL] [Abstract][Full Text] [Related]
12. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
Danahay HL; Lilley S; Fox R; Charlton H; Sabater J; Button B; McCarthy C; Collingwood SP; Gosling M
Am J Respir Crit Care Med; 2020 Apr; 201(8):946-954. PubMed ID: 31898911
[No Abstract] [Full Text] [Related]
13. A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.
Fernandez-Petty CM; Hughes GW; Bowers HL; Watson JD; Rosen BH; Townsend SM; Santos C; Ridley CE; Chu KK; Birket SE; Li Y; Leung HM; Mazur M; Garcia BA; Evans TIA; Libby EF; Hathorne H; Hanes J; Tearney GJ; Clancy JP; Engelhardt JF; Swords WE; Thornton DJ; Wiesmann WP; Baker SM; Rowe SM
JCI Insight; 2019 Apr; 4(8):. PubMed ID: 30996141
[TBL] [Abstract][Full Text] [Related]
14. Unified Airway-Cystic Fibrosis.
Cho DY; Grayson JW; Woodworth BA
Otolaryngol Clin North Am; 2023 Feb; 56(1):125-136. PubMed ID: 36266104
[TBL] [Abstract][Full Text] [Related]
15. Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia.
Gianotti A; Capurro V; Delpiano L; Mielczarek M; García-Valverde M; Carreira-Barral I; Ludovico A; Fiore M; Baroni D; Moran O; Quesada R; Caci E
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32098269
[TBL] [Abstract][Full Text] [Related]
16. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
17. Model of mucociliary clearance in cystic fibrosis lungs.
Kurbatova P; Bessonov N; Volpert V; Tiddens HA; Cornu C; Nony P; Caudri D;
J Theor Biol; 2015 May; 372():81-8. PubMed ID: 25746843
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
Kunzelmann K; Mall M
Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
[TBL] [Abstract][Full Text] [Related]
19. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
20. Mucus-targeting therapies of defective mucus clearance for cystic fibrosis: A short review.
Figueira MF; Ribeiro CMP; Button B
Curr Opin Pharmacol; 2022 Aug; 65():102248. PubMed ID: 35689870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
